We have previously shown that transport of plasma insulin into the central nervous system (CNS) is mediated by a saturable mechanism consistent with insulin binding to blood-brain barrier insulin receptors and subsequent transcytosis through microvessel endothelial cells. Since glucocorticoids antagonize insulin receptor-mediated actions both peripherally and in the CNS, we hypothesized that glucocorticoids also impair CNS insulin transport. Nine dogs were studied both in the control condition and after 7 days of high-dose oral dexamethasone (DEX) administration (12 mg/day) by obtaining plasma and cerebrospinal fluid (CSF) samples over 8 h for determination of immunoreactive insulin levels during a 90-min euglycemic intravenous insulin infusion (plasma insulin -700 pmol/1). From these data, the kinetics of CNS insulin uptake and removal were determined using a mathematical model with three components (plasma -» intermediate compartment, hypothesized to be brain interstitial fluid -> CSF). DEX increased basal insulin levels 75% from 24 ± 6 to 42 ± 30 pmol/1 (P < 0.005) and slightly increased basal glucose levels from 5.0 ± 0.7 to 5.3 ± 1.0 mmol/1 (P < 0.05). DEX also lowered the model rate constant characterizing CNS insulin transport by 49% from 5.3 x 10" 6 ± 4.0 x 10~6 to 2.7 x 10" 6 ± 1.2 x 10~6 min~2 (P < 0.001). As glucocorticoids are known to reduce CSF turnover, we also hypothesized that the model rate constant associated with CSF insulin removal would be decreased by DEX. As expected, the model rate constant for CSF insulin removal decreased 47% from 0.038 ± 0.013 to 0.020 ± 0.088 min" 1 (P < 0.0005) during DEX treatment. We conclude that DEX impairs CNS insulin transport. This finding supports our hypothesis that insulin receptors participate in the CNS insulin transport process and that this process may be subject to regulation. Moreover, since increasing brain insulin transport reduces food intake and body adiposity, this observation provides a potential mechanism by which glucocorticoid excess leads to increased body adiposity. W e have previously demonstrated that uptake of plasma insulin into the central nervous system (CNS) is mediated by a saturable mechanism consistent with insulin binding to blood-brain barrier and/or blood-cerebrospinal fluid (CSF) barrier insulin receptors and subsequent transcytosis into the CNS (1). In combination with studies demonstrating receptor-mediated transendothelial insulin transport in vitro (2), this observation strengthened the hypothesis that insulin delivery to the CNS is facilitated by endothelial insulin receptors and raised the possibility that such transport may be subject to regulation by interventions that modify insulin receptor function. To investigate this possibility, we administered the potent glucocorticoid dexamethasone (DEX) and determined its effect on plasma insulin uptake into the CNS.
W e have previously demonstrated that uptake of plasma insulin into the central nervous system (CNS) is mediated by a saturable mechanism consistent with insulin binding to blood-brain barrier and/or blood-cerebrospinal fluid (CSF) barrier insulin receptors and subsequent transcytosis into the CNS (1) . In combination with studies demonstrating receptor-mediated transendothelial insulin transport in vitro (2) , this observation strengthened the hypothesis that insulin delivery to the CNS is facilitated by endothelial insulin receptors and raised the possibility that such transport may be subject to regulation by interventions that modify insulin receptor function. To investigate this possibility, we administered the potent glucocorticoid dexamethasone (DEX) and determined its effect on plasma insulin uptake into the CNS.
DEX is well known for its capability to induce insulin resistance, as evidenced by an increase in basal plasma insulin levels and a reduction of insulin-mediated glucose disposal (3, 4) . Based on the hypothesis that this resistance reflects reduced insulin receptor-mediated responses, we postulated that transendothelial insulin transport might also be affected. Although the precise mechanism by which glucocorticoids impair insulin action is unknown, most investigations have cited insulin receptor postbinding defects as the underlying cause (5) (6) (7) (8) . Since DEX was recently shown to cause insulin resistance in rat skeletal muscle without a corresponding decrease in the GLUT4 glucose transporter, the hypothesis that glucocorticoid-induced peripheral insulin resistance is caused by reduced expression of glucose transporters seems unlikely (9) . Thus, impaired signal transduction in response to insulin receptor binding is a likely basis for this glucocorticoid effect. This observation is consistent with the possibility that insulin receptormediated transendothelial transport of insulin could also be reduced by high-dose glucocorticoid treatment.
An additional effect of DEX relevant to the current study is a decrease in CSF formation. In rabbits subjected to bilateral ventriculocisternal perfusions, addition of 1.0 or 10.0 mg/kg DEX to the perfusate decreased the rate of CSF formation by 35-40% compared with CSF formation during the initial perfusion period (10) . A similar magnitude of decreased CSF formation has been demonstrated in other animal models, including dogs, during systemic glucocorticoid administration (11) (12) (13) . Since CSF insulin removal is dependent on the rate of CSF turnover (14) , we also hypothesized that DEX would inhibit CSF insulin removal. 
RESEARCH DESIGN AND METHODS
Study animals and conditions. Nine normal adult male mongrel dogs weighing 20-30 kg were studied after an overnight fast. The animals were housed in individual cages that included a 5 X 20 ft area for exercise and were fed 0.3 kg/day of dry standard dog laboratory diet (Wayne Pro-Mix, Allied Mills, Memphis, TN) with unlimited access to water. For each study, each dog was anesthetized with thiamylal (Surital, Parke-Davis, Morris Plains, NJ), 20 mg/kg i.v., and was placed on mechanical ventilation with 1-2% halothane and 40% O 2 . Intravenous catheters were placed in fore-and hindlimbs for sampling and infusion, respectively; a 22-gauge spinal needle cannula was inserted into the cisternum magnum for sampling of CSF. Body weight was measured immediately before each study. Dog care was supervised by a licensed veterinarian. All studies were approved by the Animal Care Committee of the Seattle VA Medical Center. Insulin infusion and sampling. The study protocol consisted of a 90-min intravenous insulin infusion period with sampling of plasma and CSF for a total of 490 min. Intravenous insulin (porcine regular) was administered as a 3-min primed infusion (8.5 mU • kg" 1 • min" 1 ) commencing at t = 0 min, followed by a continuous infusion for 87 min at 20% of the primed infusion rate. Blood samples (1.8 ml) were obtained at t = -10, -5 , 1, 2, 3, 4, 6, 8, 10, 13, 16, 20, 25, 30, 35, 40, 65 , and 90 min; at 5-min intervals for 90 :£ t < 150 min; and at 20-min intervals for 150 < t < 490 min. CSF samples (0.4 ml) were obtained at t = -10, -5 , 20, 40, 65, 90, 95, 100, 110, 120, 135, and 150 min and thereafter at 20-min intervals until 490 min. Euglycemia was maintained in all studies by a variable-rate intravenous infusion of 50% dextrose with on-line monitoring of blood glucose levels using a hand-held, computerized glucose meter (Glucoscan, Lifescan, American Medical Systems, Cincinnati, OH). Blood and CSF samples were obtained and processed using the protocol described previously (1) . The average plasma insulin concentration during infusion, P ave , was determined by taking the average of plasma insulin values during the interval 1 < £ ^ 90 min after initiation of intravenous insulin infusion. Each dog was studied under normal conditions and after 7 days of oral DEX administration (0.4 mg • kg" 1 • day" 1 ). Control studies were performed in six dogs 2 weeks after their DEX studies; three dogs were studied under control conditions 2 weeks before their DEX studies. Multicompartmental model and parameter identification. A schematic illustration of the multicompartment model used to interpret the data is shown in Fig. 1 ; the description of this model and the justification of its use was previously described (1, 14) . According to this model, 
All insulin variables, INS X (£), are expressed in concentration units of picomoles per liter; all rate constants k t are expressed in min" 1 . Because the intermediate compartment was not directly sampled, only the rate constant characterizing insulin clearance from CSF, k 4 , can be identified independently. However, the product A; 1 /c 2 , which represents the throughput of insulin from plasma through the intermediate compartment and subsequently into CSF, and sum (k 2 + fc 3 ), which represents insulin flux from the intermediate compartment into CSF as well as insulin clearance from the intermediate compartment via mechanisms independent of CSF formation, can also be estimated. The mathematical modeling program SAAM (15) was used to estimate the rate constants k t k 2 (min" 2 ), k 2 + k 3 (min" 1 ), and k 4 (min" 1 ) and their associated coefficients of variation from the plasma and CSF insulin data using the method described previously (14) . Independent estimation of the CSF insulin clearance parameter, k 4 . To obtain an independent estimate of k 4 , the CSF insulin clearance parameter, insulin (porcine regular, 750 |xU in 750 |xl saline) was infused over 1 min into the cisterna magna of three dogs to which DEX (0.4 mg • kg" 1 • day" 1 ) had been administered for 7 days. The animals were studied during general anesthesia while on mechanical ventilation after an overnight fast as described above. Immediately before the infusion was administered, 750 |xl CSF was removed from the cisterna magna to preserve the original volume of CSF during the infusion. CSF samples (0.4 ml) were obtained at t = -10, -5 , 2, 5, 10, 15, 25, and 40 min and thereafter at 20-min intervals until 240 min. The resulting CSF insulin levels decayed biexponentially and were fitted to a two-compartment model representing CSF and brain interstitium (16, 17) . The CSF clearance rate was calculated by dividing the estimated bolus concentration administered by the area under the curve of the two exponentials (18) . Statistical analysis. All comparisons were made on paired data sets using a two-tailed t test. P < 0.05 was considered sufficient for rejecting the null hypothesis that no difference existed between groups.
RESULTS
Basal plasma insulin levels rose 75% during DEX administration from 24 ± 6 to 42 ± 30 pmol/1 (P < 0.005) ( Table 1) . Basal glucose levels increased slightly from 5.0 ± 0.7 to 5.3 ± 1.0 mmol/1 (P < 0.05). The mean plasma insulin level achieved during the period of intravenous insulin infusion for identification of CNS insulin uptake parameters was not significantly different between DEX and control studies (Table 1) .
Both the parameter associated with CSF insulin clearance (/c 4 ) and that associated with uptake of plasma insulin through an intermediate compartment and into CSF Qc^) decreased after DEX administration in eight of nine dogs. These decreases were readily apparent in paired CSF insulin curves. As shown in the typical CSF curve pair of Fig. 2 , both the time delay before the initial rise in CSF levels and the time at which CSF insulin levels peaked were visibly increased, indicating that the efficiency of CNS insulin transport was reduced during DEX administration. This visible effect of DEX was quantified as the mean kfa values of 5.3 x 10~6 ± 4.0 X 10~6 min" 2 in control subjects vs. 2.7 X 10~6 ± 1.2 X 10~6 min~2 during DEX administration, a 49% reduction (P ^ 0.001). Similarly, the much slower decline in CSF insulin concentration toward the basal value after DEX administration indicates decreased CSF clearance (/c 4 ). Specifically, the magnitude of the rate constant associated with CSF insulin clearance decreased 47% from 0.038 ± 0.013 to 0.020 ± 0.088 min" 1 (P < 0.0005) ( Table 1 ). In contrast, DEX was without effect on the clearance parameter for insulin in the intermediate compartment (k 2 + fe 3 ), which changed insignificantly from 0.011 ± 0.0044 to 0.012 ± 0.0039 min"
1 . The mean coefficient of variation for all estimated parameters was 47%.
To validate the model-derived parameter representing CSF insulin clearance, the mean CSF insulin clearance rate constant was also determined independently by modeling data obtained after intracisternal insulin injection in a separate group of study animals after 7 days of DEX administra- tion (n = 3). The intracisternal insulin injection protocol resulted in a characteristic time course of change in CSF immunoreactive insulin levels, illustrated in Fig. 3 . The mean CSF insulin clearance rate determined from these studies was 0.024 ± 0.0015 min"" 1 , which is within the error of the mean value of k 4 determined during intravenous insulin infusion in DEX-treated dogs (0.020 ± 0.0088 min" 1 ).
DISCUSSION
In the current studies, we investigated the effect of DEX on the kinetics of CNS insulin transport, a process mediated primarily by a saturable transport system localized within brain microvasculature. Our primary finding was that DEX decreased the efficiency of CNS insulin uptake by 49%. Combined with our previous finding that the apparent K m of the CNS insulin transport system is comparable to the K d of the insulin receptor (1), this observation is consistent with the hypothesis that insulin transport into the brain is mediated via an insulin receptor-related mechanism that is sensitive to inhibition by glucocorticoids. While other interpretations are possible, the mechanism by which other potential CNS insulin transport systems would be inhibited by steroids is unclear. These observations raise the possibility that CNS insulin transport could be subject to regulation under physiological conditions, since peripheral insulin sensitivity changes fairly dynamically (19) . The nature of the intermediate compartment in our model through which insulin passes en route from plasma to CSF has not been identified with certainty and could represent either brain interstitial fluid (ISF) or choroid plexus epithelium. Although the identity of this compartment cannot be established without direct sampling, available data support the hypothesis that this compartment is brain ISF. Insulin concentrations in rat brain extracts are ~30-40% of plasma levels (20) , whereas CSF levels are <5% of plasma levels, suggesting that insulin levels in brain ISF are considerably higher than in CSF, due to preferential uptake of insulin across the blood-brain barrier rather than the blood-CSF barrier. Moreover, blood-brain barrier endothelium expresses insulin receptors (21, 22) , and after intracarotid injection of radiolabeled insulin, penetration of an insulin tracer into brain parenchyma was inhibited by coadministration of excess insulin in newborn rabbits (23), suggesting a saturable transport process within the blood-brain barrier. Because bulk movement of brain ISF into the CSF compartment accounts for ~30% of CSF formation (24), some insulin entering ISF across the blood-brain barrier would be expected to be detected within the CSF. At present, therefore, we favor the hypothesis that the intermediate compartment represents brain ISF and that DEX reduces the efficiency with which circulating insulin enters this compartment. The parameter identified by our model to estimate CNS insulin uptake (kfa) reflects the product of the rate constants for insulin entry into the intermediate compartment from plasma (/cj and for movement from the intermediate compartment into CSF (fc 2 ). Thus, the effect of DEX to lower k v k 2 could reflect a reduction of either k l or k 2 or both. However, our observation that DEX did not affect insulin clearance from the intermediate compartment (k 2 + ^3) suggests that changes in k 2 due to DEX are unlikely to account for the observed reduction in k^2. Thus, the most parsimonious interpretation of our data is that DEX inhibited k x , which we hypothesize reflects the efficiency of insulin uptake across the blood-brain barrier.
In comparison, the inhibition of CSF insulin removal that we detected in DEX-treated animals (identified as a reduction of /c 4 ) is not expected to significantly alter insulin levels in brain ISF. Based on the assumption that brain ISF is represented by the intermediate compartment of our model, changes in the magnitude of k x k 2 or k 2 + k 3 significantly affect residence time of insulin in the intermediate compartment, whereas changes in k 4 do not. The level of insulin in CSF, having left brain ISF, does not have a significant impact on the efficiency of ISF insulin turnover.
The possibility that CNS insulin transport is a regulated process has important implications for body weight regulation, since insulin is secreted in proportion to body adiposity and appears to provide a negative feedback signal to the brain for long-term body weight regulation (22, 25) . The action of insulin in the brain to reduce food intake and body weight is well described in a number of species and is mediated by insulin receptors concentrated in areas that control feeding behavior (22) . Because brain insulin is derived largely (if not exclusively) from plasma, changes of the rate of CNS insulin transport could have important implications for the level of body weight that is maintained. Because the efficiency of insulin transport into the CNS was reduced by DEX, a potential reduction in brain ISF insulin concentration might contribute to the increased food intake and weight gain common in states of glucocorticoid excess (26) unless a compensatory increase of plasma insulin levels occurred. Although insulin secretion was not measured in the current studies, basal plasma levels increased, suggesting that some compensation occurred; therefore, it is possible that the level of CNS insulin was not; affected in our study animals. However, it is not currently possible to accurately determine the impact of DEX on brain ISF insulin levels. Moreover, the dogs in our studies could not gain weight because their food portions were fixed. Nonetheless, DEX and other glucocorticoids in excess induce obesity in adults (26) , with the majority of weight gained as fat rather than protein, implying that body adiposity regulation has been modified, and our data provide a theoretical mechanism to account for these glucocorticoid effects. The observation that glucocorticoids act directly in the brain to stimulate feeding in adrenalectomized rats (27) , however, indicates that reducing CNS insulin uptake is not the only mechanism by which glucocorticoids influence body adiposity.
The possibility that DEX administration decreases insulin receptor-mediated transport in vivo has implications for tissues other than brain tissue. Although previous in vivo studies have cited impaired insulin receptor or postbinding signaling in insulin-sensitive tissues as the primary cause of insulin resistance (5) (6) (7) (8) , studies by Yang et al. (28) have shown that insulin transport across capillaries is rate limiting for insulin action in dogs. Thus, defects in transendothelial insulin transport could contribute to the pathogenesis of peripheral insulin resistance associated with DEX and other treatments. Therefore, further work is needed to address the role of peripheral endothelial insulin transport as a determinant of changes in insulin action.
In these studies, we also found that DEX reduces the rate constant associated with CSF insulin clearance (k 4 ). Since DEX is known to decrease CSF formation (10) (11) (12) (13) and since the clearance of most CSF solutes is affected by the CSF formation rate (17), a decrease in CSF insulin removal was expected. Our ability to detect anticipated changes in the rate constants associated with plasma insulin uptake and CSF insulin clearance by our multicompartmental model supports the correctness of the model's structure. To validate our measure of the rate of CSF insulin clearance identified during systemic insulin infusion, we also determined the CSF insulin clearance rate constant after intracisternal insulin injection in DEX-treated dogs. The mean value of the CSF insulin clearance rate constant determined by this direct method (0.024 ± 0.0015 min~l) was similar to that obtained by mathematical modeling of the dynamics of CSF insulin uptake during intravenous insulin infusion (0.020 ± 0.0088 min" 1 ) . By demonstrating that model-derived parameters obtained during intravenous insulin infusion are not significantly different from those obtained by more direct means, the validity of our method of quantifying the CNS insulin uptake process is supported.
In summary, we have demonstrated that high-dose DEX administration decreases the efficiency of CNS insulin transport. This observation is consistent with a mechanism in which DEX inhibits the receptor-mediated transendothelial transport of insulin across the blood-brain barrier and/or blood-CSF barrier vascular cells, resulting in reduced efficiency of insulin uptake into the CNS.
